Ask about this productRelated genes to: FOXO3A antibody
- Gene:
- FOXO3 NIH gene
- Name:
- forkhead box O3
- Previous symbol:
- FKHRL1, FOXO3A
- Synonyms:
- AF6q21, FOXO2
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-23
- Date modifiied:
- 2015-08-25
Related products to: FOXO3A antibody
Related articles to: FOXO3A antibody
- Cisplatin is a highly effective chemotherapeutic agent used to treat various solid tumors; however, its clinical utility is limited by dose-dependent nephrotoxicity. Perampanel, an AMPA-receptor antagonist FDA-approved anti-seizure drug, has recently shown inhibitory effects on oxidative stress and inflammasome-mediated pyroptosis in neurological damage models. The current work examined the possible renoprotective benefits and clarified the underlying molecular signaling modified by perampanel in a cisplatin-renal injury model. Male Wistar rats were used to investigate the effect of perampanel (1 & 2 mg/kg/day, for 14 days) against renal injury induced by cisplatin (10 mg/kg, on the 9th day), followed by morphological, histopathological, immunohistochemical (IHC), and biochemical estimations. The administration of perampanel to cisplatin-injected rats maintained the kidney-to-body weight ratio and renal function in a dose-dependent manner. Besides, there was a great improvement in the histological features compared to the cisplatin group. IHC analysis revealed the efficient inhibitory impact of perampanel against cisplatin-induced upregulation of NF-κB p65, NLRP3, and caspase-1 expressions. Consequently, the activation of interleukin (IL)-18 and -1β inflammatory cytokines was interrupted, and their renal levels were not elevated. Eventually, the pyroptosis effector protein, gasdermin D (GSDMD), upregulation was impeded. Inflammasome inhibition by perampanel was accompanied by downregulation of the promoter signaling NF-κB p65/TNF-α, enhancement of sirtuin 3/FOXO3 antioxidant signaling alongside upregulated Nrf-2 mRNA expression and antioxidant proteins, as well as maintained balance of Bax/Bcl-2; pro-/anti-apoptotic; genes. Collectively, perampanel could attenuate cisplatin-induced renal injury through its inhibitory influence on NF-κB p65/TNF-α and NLRP3-mediated pyroptosis, in addition to enhancement of antioxidant defense and controlling apoptosis. - Source: PubMed
Publication date: 2026/04/25
Mohamed Taha BakryKhalifa Yassmen Mohamed Montaser AAttya Mina EzzatSharkawi Souty Mouner ZakyAzouz Amany A - - Source: PubMed
Publication date: 2026/04/24
Zhen ShijunZhu QingtaoWu XinzeXiong FangtaoMa WentaoWang ZishuoBo Wei - - Source: PubMed
Publication date: 2026/04/23
Lu YulanYuan YuanLiang Sheng - Left ventricular assist devices remain a major step forward for end-stage heart failure patients awaiting transplantation. We investigated the molecular basis of the longitudinal effect of left ventricular assist device implantation in both ischemic and nonischemic cardiomyopathy patients. The results revealed a common signature of 13 genes associated with glucocorticoid receptor overexpression pretransplantation, independent of the etiology. Four key molecular hub genes from this signature were highlighted, involved respectively in metabolic plasticity (PDK4), limited inflammation (FKBP5 and ZBTB16), and repair (FOXO3). It shows, however, that these pathways contribute to cardiac homeostasis. - Source: PubMed
Publication date: 2026/04/21
Mury PaulineDagher OlinaNoly Pierre-EmmanuelDucharme AniqueGramolini ShreyaBillia FilioThorin Eric - Extranodal natural killer/T-cell lymphoma (ENKTL) is clinically characterized by destructive lesions that first appear in the nasal cavity and progress along the midline of the face. It was historically described as "rhinitis gangrenosa progressiva" or "lethal midline granuloma" due to its destructive clinical nature and had significant diagnostic and therapeutic challenges. This review synthesizes about 40 years of research, beginning with the 1980s and 1990s, when the disease was identified as a T-cell- or NK-cell-derived lymphoma, and the authors' discovery that clearly linked it to Epstein-Barr virus (EBV). ENKTL is highly prevalent in East Asia and characterized by a type II EBV latency pattern, in which the oncoprotein latent membrane protein 1 (LMP1) acts as a central driver of pathogenesis, activating critical signaling pathways including JAK/STAT, NF-κB, PI3K/Akt, and RAS/MAPK. These pathways, often bolstered by mutations in genes, trigger an oncogenic cascade involving epigenetic modifiers-enhancer of zeste homolog 2 (EZH2), histone deacetylase (HDAC). The deletion of chromosome 6q, leading to loss of function of tumor suppressor PR domain zinc finger protein 1 (PRDM1) and forkhead box O3 (FOXO3), as well as transcription of TNF α-induced protein 3 (TNFAIP3) and protein tyrosine phosphatase receptor type kappa (PTPRK), also contributes to pathogenesis. In vitro studies by the author's group demonstrated that autocrine/paracrine positive feedback loops involving several pro-proliferative molecules/cytokine/chemokine-CD27, ICAM1, hepatocyte growth factor (HGF), IL-9, IL-10, IL-15, CCL17, CCL22, CXCL10- further amplify ENKTL proliferation. Diagnostic precision has improved through the use of serum EBV DNA copy numbers and viral microRNAs (miRs), specifically miR-BART2-5p, alongside the emergence of soluble CD27 as a novel biomarker. While early anthracycline-based regimens failed due to multidrug resistance (MDR), modern concurrent chemoradiotherapy composed of MDR-independent drugs has significantly improved 5-year overall survival (OS) rates for localized disease to over 80%. For advanced or relapsed/refractory cases, L-asparaginase-based regimens are standard, though outcomes remain unsatisfactory. The therapeutic paradigm is currently shifting toward chemoradiotherapy combined with either immune checkpoint inhibitors or small-molecule drugs. Future research should focus on novel molecular-targeted therapies, immunotherapies, or combination strategies targeting proliferation-related molecules or LMP1. - Source: PubMed
Publication date: 2026/04/17
Harabuchi Yasuaki